| First Author | Zhao F | Year | 2018 |
| Journal | Am J Pathol | Volume | 188 |
| Issue | 8 | Pages | 1754-1767 |
| PubMed ID | 29803830 | Mgi Jnum | J:263894 |
| Mgi Id | MGI:6192825 | Doi | 10.1016/j.ajpath.2018.04.011 |
| Citation | Zhao F, et al. (2018) Cause and Effect Relationship between Changes in Scleral Matrix Metallopeptidase-2 Expression and Myopia Development in Mice. Am J Pathol 188(8):1754-1767 |
| abstractText | Myopia is a serious sight-compromising condition in which decreases in scleral biomechanical strength are associated with protease up-regulation resulting in thinning of its collagenous framework and changes in the extracellular matrix composition. Matrix metallopeptidase (MMP)-2 is one of the known proteases mediating these alterations. To determine whether MMP-2 up-regulation precedes myopia development, the direct effects of gain and loss in Mmp2 gene function were evaluated on refractive development and form deprivation myopia in mice. Four weeks after injecting an adeno-associated virus serotype 8 packaged Mmp2 overexpression vector (AAV8-Mmp2), scleral MMP-2 up-regulation was accompanied by significant myopia in a normal visual environment. In contrast, AAV8 packaging with shRNA targeting Mmp2 inhibited rises in MMP-2 expression induced by form deprivation by 54% and reduced myopia development by 23% compared with eyes injected with an irrelevant scrambled sequence. Because opposing changes in MMP-2 protein expression levels had corresponding effects on myopia progression, up-regulation of this protease contributes to inducing this condition. This notion of a cause-and-effect relationship between MMP-2 up-regulation and myopia development is supported by showing that form-deprived myopia development was attenuated by 27% in fibroblast-specific Mmp2 deletion (S100a4(cre)Mmp2(fl/fl)) mice relative to Cre-negative littermates (Mmp2(fl/fl)). Therefore, MMP-2 is a potential drug target for inhibiting myopia progression. |
